Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study.
Yu-Qian Sun, Ting-Ting Han, Yu Wang...
https://pubmed.ncbi.nlm.nih.gov/33718234/Actively Recruiting
Led by Peking University People's Hospital · Updated on 2026-09-14
307
Participants Needed
1
Research Sites
N/A
Total Duration
Elderly patients with acute myeloid leukemia AML typically have a poor outlook when treated with conventional chemotherapy. Allogeneic hematopoietic stem cell transplantation allo-HSCT can improve long-term survival but is limited by high transplantation-related mortality TRM. Current research aims to reduce TRM in elderly AML patients by optimizing conditioning regimens before transplantation. This study compares two conditioning regimens, BuFluCyATG and BuCyATG, to evaluate their impact on TRM in elderly AML patients undergoing haploidentical HSCT. The study evaluates two conditioning regimens given before haploidentical hematopoietic stem cell transplantation. The BuFluCyATG regimen involves a combination of Ara-C, busulfan, fludarabine, cyclophosphamide, and ATG administered intravenously over specific days before transplantation. The BuCyATG regimen uses Ara-C, busulfan, cyclophosphamide, and ATG with different dosing schedules. Participants will be randomly assigned to receive one of these regimens to determine if the BuFluCyATG regimen reduces TRM compared to BuCyATG. Participants will be followed from transplantation through 12 months post-treatment to monitor transplant-related mortality, toxicity of conditioning at 28 and 100 days, engraftment, graft-versus-host disease GVHD, overall survival, relapse rates, leukemia-free survival, event-free survival, and viral infections. The study includes assessments such as blood tests and clinical evaluations during this follow-up period to measure these outcomes and evaluate safety and effectiveness.
CONDITIONS
Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.
Y
Yuqian Sun
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Peking University People's Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 10 days
Participants receive one of two conditioning regimens, Bu/Flu/Cy/ATG or Bu/Cy/ATG, before undergoing haploidentical hematopoietic stem cell transplantation.
Daily visits during conditioning period
Duration - 12 months
Participants are monitored for transplant-related mortality, toxicity, engraftment success, graft-versus-host disease, overall survival, relapse, leukemia-free survival, event-free survival, and viral infections up to 12 months after transplantation.
Regular follow-up visits during this period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yu-Qian Sun, Ting-Ting Han, Yu Wang...
https://pubmed.ncbi.nlm.nih.gov/33718234/Y-Q Sun, L-P Xu, X-H Zhang...
https://pubmed.ncbi.nlm.nih.gov/25599162/Xiao-Jun Huang, Hong-Hu Zhu, Ying-Jun Chang...
https://pubmed.ncbi.nlm.nih.gov/22535659/Nicole Santoro, Myriam Labopin, Fabio Ciceri...
https://pubmed.ncbi.nlm.nih.gov/30620383/Peking University People's Hospital
Lead Sponsor